CDK2 and triple-negative breast carcinoma: CYC065, a CDK2/9 inhibitor, could induce decreased cell migration/invasion and impede the epithelial-mesenchymal transition (EMT) program in triple-negative breast cancer mainly through inhibition of CDK2-mediated phosphorylation of Smad333.